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Background
Transfusion of blood components is widely utilized in the management of
medical and surgical conditions. With the discovery of blood types and advancements
in medicine, transfusion can be a life-saving intervention. One of the most important
reasons for red blood cell (RBC) transfusion is to restore, or maintain, oxygen delivery to
vital organs in the human body. Fresh frozen plasma (FFP) transfusion is utilized to treat
coagulopathies, life threatening bleeding diathesis and reverse effects of warfarin.
Cryoprecipitate is indicated for the treatment of von Willebrand’s disease, Hemophilia
A, Factor XIII deficiency and hypofibrinogenemia, especially when recombinant products
are not available. In 2003, the National Blood Data Resource Center estimated that 14
million units of whole blood were collected, processed into 27 million units of blood
products and subsequently transfused in to 4.5 million medical and surgical patients in
the United States.1 Though transfusion is a life-saving intervention, there is continuing
debate about the standardization of blood transfusion practices. Not only has blood
become a scarce resource in a large growing population, but transfusion of blood and
blood products also carry significant risks.
Oxygen is carried in red blood cells and reversibly bound to the tetramer
hemoglobin. Adequate oxygenation of the tissues is dependent on the balance of
oxygen consumption and oxygen delivery. Oxygen consumption can remain constant
over a wide range of oxygen delivery. However as oxygen delivery reaches a critical
threshold, tissue extraction of oxygen cannot be further increased to meet the
metabolic needs of the tissue. Oxygen delivery below the critical threshold results in
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the beginning of anaerobic metabolism and the production of substrates such as lactate,
nicotinamide adenine dinucleotide (NADH), and reduced cytochrome oxidase. This
critical threshold of oxygen delivery occurs at different levels in different organ systems.
The critical threshold is dependent on the regional and global blood flow regulation, as
well as the metabolic needs of the organs.
Oxygen delivery (DO2) to the whole body is dependent on the relationship
between cardiac output (CO) and oxygen content (CaO2) in the arterial blood [equation
1]. Oxygen consumption (VO2) in the whole body is dependent on cardiac output and
the oxygen content difference between arterial (CaO2) and venous blood (CvO2)
[equation 2].
DO2 = CO × CaO2 (normal range: 460 to 650 mL/min/m2)
[equation 1]
VO2= CO × (CaO2– CvO2) (normal range: 96 to 170 mL/min/m2)
[equation 2]
Where:
CaO2 = (Hb × 1.39 × SaO2) + (0.003 × PaO2)
CvO2 = (Hb × 1.39 × SvO2) + (0.003 × PvO2)
Hb, hemoglobin; SaO2, arterial oxygen saturation; PaO2, arterial oxygen
tension; SvO2 mixed venous oxygen saturation; PvO2, mixed-venous oxygen
tension

Reduction in whole body oxygen delivery can therefore result from either,
decrease in cardiac output, or decrease in arterial blood oxygen content (profound
anemia, massive hemorrhage, hypoxemia, and decrease in oxygen saturation). In
addition to cardiac output and arterial blood oxygen content influencing whole body
oxygen delivery, microvascular capillary regulatory mechanisms can also affect tissue

Page |3

oxygen delivery. Functional physiologic shunting can decrease tissue oxygen delivery,
while pharmacologic manipulation of microvasculature can increase tissue oxygen
delivery.2
Theoretically, red blood cell transfusion is capable of enhancing arterial blood
oxygen content, and thereby increasing total whole body oxygen delivery. However the
use of red blood cell transfusion to manipulate and potentially increase tissue oxygen
delivery is complex and its efficacy is not completely clear.3-7 Transfusion increases
hemoglobin levels (hence increase in oxygen content) and in cases where there is a
reduction of preload, transfusion can additionally increase cardiac output and thus total
body oxygen delivery. However, increasing hemoglobin levels and oxygen content via
transfusion may not lead to the immediate desired result of increase oxygen delivery at
the tissue level.8-12 The transfusion of stored red blood cells can trigger biochemical and
inflammatory reactions and potentially result in decreased oxygen delivery at the tissue
level.8-12
Fresh frozen plasma is one of the least understood blood products. It contains
albumin, globulins, fibrinogen and other coagulation factors. Even though it has limited
recommendations for its use, it is most often used to treat bleeding disorders when a
coagulation factor or multiple coagulation factors are deficient or no coagulation factorspecific concentrate is available.13 Recommended uses for fresh frozen plasma are
listed in table 1. Fresh frozen plasma is the most frequently misused blood product. 14,15
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Table 1. Recommended uses for FFP
Single coagulation factor deficiencies
Multiple coagulation factor deficiencies with severe bleeding in disseminated
intravascular coagulation (DIC)
Thrombotic thrombocytopenic purpura (TTP)
Reversal of warfarin effect
Surgical bleeding and hemostasis
Hemorrhagic disease of the newborn
Neonates with coagulopathy and in need for a surgical procedure
Red cell T antigen in newborns

Cryoprecipitate is the portion of the plasma that is rich in coagulation factors,
including factor VIII, fibrinogen, von Willebrand factor and factor XIII.13 Cryoprecipiate is
used primarily for the reversal of hypofibrinogenemia caused by massive transfusion or
disseminated intravascular coagulation (DIC). It is also considered for use in treatment
of von Willenbrand’s disease, Hemophila A, and Factor XIII deficiency when recombinant
products are not available.
Platelets are administered to treat either thrombocytopenia or provide
functional platelets. Thrombocytopenia, a decrease in number of circulating platelets, is
caused by either an increased destruction (idiopathic, immunologically-mediated, DIC)
or decreased production of platelets (myelosuppressive drugs, radiation, chronic alcohol
use).
Blood component therapy can be potentially life-saving and at the same time
can have deleterious effects. Thus transfusion of blood products should not be taken
lightly. Ideally blood product should only be transfused when necessary. If clinicians
could easily monitor for optimal oxygen delivery and coagulation status, blood product
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transfusions could be optimized. However, in rapidly changing clinical situations, it is
challenging to predict the need for blood products precisely. With this in mind,
transfusion triggers or thresholds based on measurable physiological parameters, could
aid and guide clinicians in making the decision for transfusion therapy. It is expected
that these transfusion thresholds are developed from quality evidence and based on
rigorous clinical trials and studies that demonstrate improvement in patient outcomes.

History of Perioperative Transfusion
There is significant variability in transfusion practices among the different
medical specialties. Historically, a hemoglobin of 10 g/dL and a hemotocrit of 30% were
widely used and accepted as “transfusion triggers” for red blood cell transfusion
particularly in the surgical setting.16 In the 1970s, red blood cells were often times
withheld until symptoms of anemia developed or there was a clinically significant drop
of <10 g/dL in hemoglobin.17-19 In 1988 the National Heart, Lung and Blood institute, the
Office of Medical Applications of Research, the Warren Grant Magnuson Clinical Center
of the National Institute of Health, and the Food and Drug Administration convened the
Consensus Development Conference on Perioperative Red Cell Transfusion to discuss
the criteria for perioperative red blood cell transfusion, the morbidity of anemia in the
perioperative period, and immediate and long-term risks of transfusion. This consensus
conference concluded that available evidence at the time did not support a single
criterion for red blood cell transfusion, mild-moderate anemia did not contribute to
perioperative morbidity, and transfusions should be kept to a minimum due to the
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documented risks of infection and deleterious immune modulation.20 The consensus
conference concluded that future research was necessary to define the best indications
for perioperative red blood cell transfusion.
Different authors have suggested a range of hemoglobin levels as criterion for
transfusion (6.0-10.0g/dL), depending on the presence of several co-morbidities.21-23 In
1999, the Canadian Critical Care Trials Group demonstrated that a restrictive strategy of
red blood cell transfusion in 838 critically ill patients reduced hospitalization mortality
rates in a multicenter, randomized controlled clinical trial referred to as the Transfusion
Requirements in Critical Care (TRICC) trial.24 Except in patients with acute myocardial
infarction and unstable angina, a restrictive transfusion strategy (threshold of
hemoglobin 7.0g/dL; hemoglobin range of 7.0-9.0g/dL) was as effective, if not
significantly better at lowering hospital mortality rates, than a liberal transfusion
strategy (hemoglobin threshold of 10.0g/dL; hemoglobin range of 10.0-12.0g/dL).
In 2001, a randomized controlled clinical trial was performed to determine if a
low transfusion threshold was safe in critically ill patients with known cardiovascular
disease.25 This study concluded that there was no difference in mortality or myocardial
infarction rates in the restrictive (transfusion threshold of hemoglobin 7.0g/dL;
hemoglobin range 7.0 - 9.0g/dL) versus liberal (transfusion threshold of hemoglobin
10.0g/dL; hemoglobin range 10.0 - 12.0g/dL) transfusion groups.25 However, it
suggested that a restrictive transfusion strategy appeared to be safe in most patients
with cardiovascular disease, with the exception of patients with acute myocardial
infarcts and unstable angina. On the contrary, in other studies, in patients undergoing
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coronary artery bypass graft surgery or myocardial revascularization there was no
difference in mortality rates when a restrictive (hemoglobin 8.0g/dL) transfusion
threshold was compared to a liberal (9.0g/dL) transfusion threshold. 26,27
In contrast to packed red blood cells, there is little data on the relationship of
transfusion of coagulation blood products, such as platelets, fresh frozen plasma,
cryoprecipitate, and patient outcomes. Of the coagulation blood products mentioned,
there are more data about the transfusion of platelets in the perioperative period. In
2004, a study with 1,720 patients who received platelet transfusion, suggested a
significant association between platelet transfusion and the risk of infection, stroke and
death.28 There have been no prospective randomized trials to date investigating the
liberal or prophylactic use of platelet transfusion and its association with increased rate
of stroke and death. Moreover, there is limited data from randomized controlled trials
regarding the threshold for transfusion of fresh frozen plasma and cryoprecipitate, and
patient outcomes.

Risks of Blood Product Transfusion
More than twenty years ago, blood and blood component transfusion were
thought to be relatively safe. Then in the 1980s, up to 1 in 100 blood units in the United
States was found to transmit the human immunodeficiency virus (HIV) or hepatitis C
virus (HCV), as plasma did not undergo viral inactivation.29 There have been significant
advancements in transfusion medicine in the past 30 years, such as nucleic-acid testing,
that have reduced the estimated residual risk of infection with the HIV or HCV to 1 in 1.5
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million to 1 in 2 million units transfused.30 Current risk of transmission of blood-borne
viruses are listed in table 2.31
Table 2. Contemporary risk of transmitting any of the blood-borne viruses.31
Virus
Human Immunodeficiency
Virus 1&2
Hepatitis C Virus
Hepatitis B Virus
Human T-lymphotrophic
Virus
West Nile Virus
Parvovirus B19
Hepatitis A/E

Risk per Unit
Transfusion
1:2,135,000

Transmission
Rate
90%

Window
Period
11 days

1:1,935,000
1:205,000
1:3,000,000

90%
70%
30%

10 days
59 days
51 days

1:10,000 to 1,000*
1:40,000 to 3,000
1:1,000,000

unknown
low
low

-

*prior to nucleic acid testing

Emerging infections, defined as those infections whose incidence in humans has
increased within the past two decades or threatens to increase in the near future, may
have an asymptomatic blood-borne phase and may exist and can be transmittable by
transfusion. Current infectious agents that are emerging to threaten blood and blood
component safety include, but are not limited to, are: human variant Creuztfeld-Jakob
disease, West Nile virus, Babesia species, GB virus C-hepatitis G virus, SEN virus, TT
virus, human herpesvirus 8, and simian foamy virus.32-34
Though transmission of infection by blood transfusion has decreased
significantly, transfusion-related acute lung injury (TRALI) has now become the leading
cause of transfusion related mortality. Fresh frozen plasma administration has been
shown to be an independent risk factor for TRALI in trauma, medical and surgical ICU
patient populations in the United States.35 Intensive care unit patients, enrolled in the
2004 CRIT (Anemia and Blood Transfusion in CRITical Care) study, who received red
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blood cell transfusions experienced a higher incidence of overall complications. The
study demonstrated that the number of red blood cell transfusions a patient received
was independently associated with a longer ICU stay, length of hospital stay, and
increase in mortality.36 With these current transfusion risks in mind, practitioners are
relying heavily on transfusion practice guidelines and recommendations. The goal of
these clinical transfusion practice guidelines and recommendations is to limit
unnecessary transfusion of blood products, improve blood component transfusion
therapy for patients and hopefully improve clinical outcomes.

History of the Development of Transfusion Guidelines
The development of guidelines were proposed in 1990 by the Institute of
Medicine to reduce inappropriate health care variation by aiding physician decisionmaking.37 Decision-making in healthcare should acknowledge benefits and risks of
medical interventions, as well as the underlying quality of evidence to support such
interventions.
The number of practice guidelines has mushroomed significantly, with each of
the medical societies developing their own set of guidelines for areas of interest for
them. 38 A variety of medical specialties have published recommendations, on the use of
blood products, to guide clinicians in their transfusion decisions. In the 1980s, the
National Institute of Medicine held consensus conferences on the use of red blood cells,
fresh frozen plasma, and platelets.39-41 In the 1990s, the American College of Physicians
and American College of Pathologists issued guidelines regarding red blood cell and
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fresh frozen plasma, cryoprecipitate and platelet transfusion respectively.42,43 The
American Association of Blood Banks also generated guidelines regarding transfusion
during coronary artery bypass graft surgery and appropriate blood utilization. 44,45 In the
same decade, the American Society of Anesthesiologists (ASA) developed a Task Force
to develop guidelines regarding blood component therapy.46 However, the
consequence of numerous guidelines from multiple specialties results in varying
recommendations for each intervention, which can be confusing for physicians.
Furthermore, when several physicians are involved in the care of a patient, their
decisions when to transfuse can differ significantly, based on what guideline the caregiver is following.
Guidelines for physicians should comprise of the following: the scope of the
practice guidelines, current interventions and practices considered, strength of
recommendations and the quality of used evidence. The recommendations developed
in guidelines ideally should be based on strong evidence. However in actuality,
guidelines may generate strong recommendations on consensus expert opinions rather
than on high quality evidence.37 In addition, these guidelines use multiple systems to
grade the quality of evidence, as well as to classify the strength of their
recommendations. Thus, it is important to compare and analyze current guidelines, to
determine variations in recommendations and if the recommendations generated to
guide clinicians are truly supported by quality evidence. In addition, it is also important
to consider and evaluate guidelines for the composition of their working group, types of
studies used to develop guidelines, and the specific methodologies utilized to grade
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evidence and classify recommendations. In this thesis, we compared different guidelines
for variations in guideline development, recommendations and their level of evidence.

Methods
A comprehensive literature search on clinical transfusion guidelines of blood
components was identified and performed using the following computer databases:
PubMed/Medline, Cochrane Central, Scopus and the National Guideline Clearinghouse.
Additional websites and publications of relevant scientific societies, such as the
Australian and New Zealand Society of Blood Transfusion, were also searched for
guidelines missed from the computer database search. Key words that were used for
searching the databases include the combination of the following keywords: blood,
blood component, blood product, transfusion, guidelines. Of those database searches
of articles, only articles from January 2005 to October 2010 written in the English
language were retrieved. The articles/guidelines were limited to the last 5 years as we
assumed that the literature within that time frame was most current and clinically
relevant. However some guidelines outside of this time period were included, in order
to provide complete representation of guideline recommendations from countries not
represented in the initial computer database searches. In these cases, only the most
current practice guideline published from the societies were utilized. Relevance of the
articles to be retrieved was evaluated and included if there were clear transfusion
indications and recommendations stated within the article. Articles regarding
transfusion practices in children or neonates were not included in this study. A total of
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eleven international guidelines were included in this study for final analysis ranging from
the year 2001 to 2010.
The resulting eleven guidelines were analyzed for the following areas:
characteristics and composition of the guideline working group panel, literature and
evidence utilized for the systematic review, databases utilized to retrieve evidence and
literature for the systematic review, methodologies employed by guideline committees
to grade strength and quality of evidence and recommendations, quantity of
recommendations suggested, and specific transfusion thresholds and/or clinical settings
for transfusion of blood products.
The eleven guidelines use seven different systems to grade the strength of
recommendations and the level of evidence. In order to help us compare the level of
evidence and strength of recommendations amongst these guidelines, we developed a
three-tiered classification system for both grading level of evidence and strength of
recommendation (Table 2 and 3). This system was applied to all eleven guidelines
reviewed. The terms “strong,” “intermediate,” and “low” level of evidence as used in
this thesis are described and defined in table 3. The terms “strong,” “intermediate,”
and “low” grade of recommendation as used in this thesis are described and defined
table 4.
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Table 3. Compilation of Level of Evidence Grading
Grading of
Evidence

GRADE

AHRQ

STRONG

High/A

1A

INTERMEDIATE

Moderate/B

1B
2A

Low /C

2B
3

Very Low /D

4

LOW

USPSTF
(After
May
2007)
High
(Class I)

USPSTF
(Before
May
2007)
Good

AHA/ACC

NHMRC

ASA

A

I

Support

Moderate
(Class II)

Fair

B

II
III1

Suggest

C

III2
III3

Equivocal

Low
(Class III)

Poor

IV

Silent
Insufficient
Inadequate

AHA/ACC

NHMRC

ASA

Class I

A

B
C

Class IIa

B

Strongly
agree
Agree
Equivocal

D

Class IIb
Class III

C

Disagree

D

Strongly
disagree

GRADE = Grading of Recommendations, Assessment, Development, and Evaluation
USPSTF = U.S. Preventative Task Force
ACC/AHA = American College of Cardiology/American Heart Association
ASA = American Society of Anesthesiologists
NHMRC = Australian National Health and Medical Research Council
ARHQ = Agency for Healthcare Research and Quality

Table 4. Compilation Strength of Recommendation Classification
Strength of
Recommendation

GRADE

STRONG

Strong
(1)

INTERMEDIATE

WEAK

Weak
(2)

AHRQ

USPSTF
(After
May
2007)
A (Level
1)
B (Level
2)
C
D (Level
3)
I

USPSTF
(Before
May
2007)
A

I

GRADE = Grading of Recommendations, Assessment, Development, and Evaluation
USPSTF = U.S. Preventative Task Force
ACC/AHA = American College of Cardiology/American Heart Association
ASA = American Society of Anesthesiologists
NHMRC = Australian National Health and Medical Research Council
ARHQ = Agency for Healthcare Research and Quality
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Results
The bibliographic search conducted was limited to articles written in the English
language published during the period from January 2005 to October 2010. A
comprehensive literature search to identify guidelines relevant to transfusion of blood
components was performed and yielded the following results: PubMed/Medline (701),
Cochrane Central (38), Scopus (4,292), and the National Guidelines Clearinghouse
(2,073). Additional publications from relevant scientific societies, such as the Australian
and New Zealand Society of Blood Transfusion, were also searched to identify guidelines
missed from the database screen. An initial screening of these references identified
potentially relevant articles. The final analysis of these articles resulted in the
identification of 11 international guidelines addressing clinical transfusion practices of
blood components.

Guidelines Working Group Panel Composition
Table 5 and figure 1 report the panel composition of working groups for each of
the eleven guidelines. To address the composition of working groups that prepared
guidelines we looked at the number of total members, medical specialties represented,
international/national societies represented, and consulting methodologists involved in
the working group panels. Six of eleven guidelines reported the number of medical
specialties represented by each panel member. However, only five guidelines detailed
the number of international/national medical societies represented by each panel
member. Similarly, five of eleven guidelines reported the total number of members
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composed their working group. Only two of eleven guidelines reported involving
consultant methodologists in the working group panel.

Table 5. Working Group Panel Composition
Author

Roback et al (2010)
Napolitano et al
(2009)
Dellinger et al (2008)
Ferraris et al (2007)
Spahn et al (2007)
Stainsby et al (2006)
Wong et al (2007)
Droubatchevskaia et
al (2007)
ASA Task Force
(2006)
New Zealand (2001)
Cochrane (2009)
(“NM “ indicates not mentioned)

Number of
members

Number of
specialties
represented

Number of
societies
represented

Number of
consulting
methodologists

17
NM

6 (9 members)
5

6
2

3
NM

55
17
NM
100
NM
NM

NM
NM
5
NM
2
3

16
NM
5
3
NM
NM

NM
NM
NM
NM
NM
NM

10

4

NM

2

NM
NM

3
NM

NM
NM

NM
NM
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Figure 1. Number of Members in Working Group Panel

Table 6 and figure 2 report the number of medical specialties represented in
each working group panel for the eleven guidelines. Six of the eleven guidelines
reported having a panel member specialized in internal medicine and/or critical care
medicine. Five of the eleven guidelines reported having a panel member specialized in
hematology, anesthesiology, or surgery. Within the guidelines mentioning a panel
member specializing in surgery, three specified having a member from trauma and/or
thoracic surgery. Three of the eleven guidelines also reported having a panel member
specialized in pathology. Pediatrics, obstetrics, transfusion pathology, oncology,
transfusion medicine were mentioned to be represented in only one of the guidelines.

P a g e | 17

One of eleven guidelines reported five medical specialties represented, three of eleven
guidelines reported four medical specialties represented, one of eleven guidelines
reported three medical specialties represented, two of eleven guidelines reported two
medical specialties represented, and two of eleven guidelines reported only one medical
specialty represented in the working group panel. Emergency medicine, pediatrics and
obstetrics specialties were reported in the working group panel of only one guideline.
Orthopedic surgery, vascular surgery, oncologic surgery, solid organ transplant surgery
and neurosurgery were not represented (or mentioned) in any of the eleven guidelines.
Table 6. Medical Specialties Represented in Working Group Panel
Author

Hematology

Pathology

Anesthesiology

Internal
Medicine/Cri
tical Care

Emergency
Medicine

Pediatrics

Surgery
(Thoracic/
Trauma)

Obstetrics

Total
Number of
Specialties

Roback et al
(2010)

X (9)

X (9)

X(2)

X (4)

NM

X(2)

NM

NM

5

Napolitano
et al (2009)

NM

NM

NM

X (?)

NM

NM

X (?/Trauma)

NM

2

Dellinger et
al (2008)

NM

NM

NM

X (?)

NM

NM

NM

NM

1

Ferraris et
al (2007)

NM

NM

X

NM

NM

NM

X (Thoracic)

NM

2

Spahn et al
(2007)

X

NM

NM

X

X

NM

X (?/Trauma)

NM

4

Stainsby et
al (2006)

X

NM

NM

NM

NM

NM

NM

NM

1

Wong et al
(2007)

X

X

X

X
(Transfusion)

NM

NM

NM

NM

3

Droubhatch
evskaia et
al (2007)

X

X

NM

X

NM

NM

NM

NM

3

ASA Task
Force
(2006)

NM

X
(Transfusion)

X

NM

NM

NM

X

X

4

New
Zealand
(2001)

X

NM

X

X (Oncology)

NM

NM

X

NM

4

NM

NM

NM

NM

NM

NM

NM

NM

NM

Cochrane
(2009)

(“NM “ indicates not mentioned)
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Figure 2. Number of Medical and Surgical Specialties Represented

Evidence and Systematic Reviews Utilized to Generate Guidelines
Table 7 demonstrates the study design of the evidence utilized in the
development of the eleven guidelines. Four of the eleven guidelines reviewed listed
detailed methods of their literature review and their study design of the literature
searched and reviewed. One guideline only mentioned the study designs they excluded
from their literature search. Five of eleven guidelines analyzed in this study did not
reveal the study designs of the literature they utilized in their search and in the
development of their guidelines.
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Table 7. Systematic review: Study Design of Evidence Utilized
Author

Roback et al (2010)
Napolitano et al
(2010)
Dellinger et al
(2008)
Ferraris et al (2007)
Spahn et al (2007)
Stainsby et al
(2006)
Wong et al (2007)
Droubatchevskaia
et al (2007)
ASA Task Force
(2006)
New Zealand
(2001)
Cochrane (2009)

Randomized
Controlled
Trials
X

Case
Control

Case
Reports

Observational

Systematic
Reviews

Metaanalysis

Guidelines

Abstracts

Editorials

X
excluded

excluded

Excluded

NM
X
X

X
X

X

X
X

X

X

X

NM
NM
NM
NM
X

X

NM

(“NM “ indicates not mentioned)

Table 8 demonstrates the databases utilized to yield the literature searches and
reviews performed by each working group for the eleven international guidelines. Six of
the eleven guidelines utilized Pubmed/Medline searches and four of the eleven
guidelines utilized Cochrane Central searches. One guideline utilized EMBASE, one
guideline utilized National Library of Medicine, and another guideline utilized Current
Contents. Four of the eleven guidelines did not reveal the types of databases utilized
when performing their literature searches for their guideline development.
Table 8. Systematic review: Databases Utilized
Author

Roback et al (2010)
Napolitano et al (2010)
Dellinger et al (2008)
Ferraris et al (2007)
Spahn et al (2007)
Stainsby et al (2006)
Wong et al (2007)
Droubatchevskaia et al
(2007)
ASA Task Force (2006)
New Zealand (2001)
Cochrane (2009)
(“NM “ indicates not mentioned)

Medline/PubMed

EMBASE

X
X

X

X
X
X

X

Cochrane
Central
NM
X

National
Library of
Medicine

Current
Contents

X

NM
X
X

NM
NM
X

X
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Methodology Utilized to Grade Evidence
Table 9 reports the methodology utilized by the eleven guideline’s working
groups to grade and rate evidence. Three of the eleven guidelines either utilized the
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE)
methodology, or the Agency for Healthcare Research and Quality (AHRQ)
methodology.47-51 The five guidelines not utilizing the GRADE or AHRQ methodologies,
utilized any one of the following: the U.S. Preventative Task Force (USPSTF)
methodology, American College of Cardiology/American Heart Association (ACC/AHA)
methodology, Australian National Health and Medical Research Council (NHMRC)
methodology or the American Society of Anesthesiologists (ASA) methodology.52-55
Table 9. Methodology utilized by Guideline Committees to Rate Evidence
Author
GRADE
USPSTF
ACC/AHA
ASA
NHMRC
Roback et al (2010)
X
Napolitano et al (2010)
X
Dellinger et al (2008)
X
Ferraris et al (2007)
X
Spahn et al (2007)
X
Stainsby et al (2006)
Wong et al (2007)
Droubatchevskaia et al
(2007)
ASA Task Force (2006)
X
New Zealand (2001)
X
Cochrane (2009)
TOTAL
3
1
1
1
1
GRADE = Grading of Recommendations, Assessment, Development, and Evaluation
USPSTF = U.S. Preventative Task Force
ACC/AHA = American College of Cardiology/American Heart Association
ASA = American Society of Anesthesiologists
NHMRC = Australian National Health and Medical Research Council
ARHQ = Agency for Healthcare Research and Quality

ARHQ

Cochrane

X
X
X

3

X
1
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Practice Guideline Recommendations
Table 10 and figure 3 represent the total number of recommendations made by
the working group panel regarding use of blood and blood product transfusion in the
perioperative setting. The total number of recommendations ranged from one to
twenty-eight total recommendations for each of the guidelines. A total of 107
recommendations were generated about packed red blood cells, fresh frozen plasma,
platelets, and cryoprecipitate transfusion. Of the 107 recommendations, 48 (48.86%) of
the recommendations were specific to the use of packed red blood cells, 31 (28.97%) of
the recommendations were specific to the use of fresh frozen plasma, 15 (12.02%) of
the recommendations were specific for the use of platelets, and only 13 (12.15%)
recommendations were specific to the use of cryoprecipitate. (Figure 3)
Table 10. Number of Recommendations Suggested for each Component of Blood
Therapy
Author

Roback et al (2010)
Napolitano et al
(2010)
Dellinger et al (2008)
Ferraris et al (2007)
Spahn et al (2007)
British Columbia
(2006/2007)
ASA Task Force (2006)
New Zealand (2001)
Cochrane (2009)
TOTAL

Packed Red
Blood Cells

Fresh Frozen
Plasma

Platelets

Cryoprecipitate

1
28

6
0

0
0

0
0

Total
Regarding
Blood
Products
7
28

2
9
1
1

1
0
1
11

1
0
3
7

0
0
1
2

4
9
6
21

2
3
1
48/107
(48.86%)

5
7
0
31/107
(28.97%)

3
6
0
15/107
(12.02%)

3
2
0
13/107
(12.15%)

8
14
1
107/107
(100%)
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Figure 3. Total Number of Recommendations

Of the 107 recommendations, table 11 and figure 4 demonstrate that only 12
(11.21%) recommendations were generated from “strong” level evidence, 25 (23.36%)
recommendations were generated from “intermediate” level evidence, and 70 (65.42%)
recommendations were generated from “low” level evidence.

Table 11. Level of Evidence Utilized for All Blood Product Recommendations
Level of Evidence
STRONG
INTERMEDIATE
LOW
Total

Packed Red
Blood Cells
4 (8.33%)
24 (50.00%)
20 (41.67%)
48

Fresh Frozen
Plasma
7 (22.58%)
1 (3.23%)
23 (74.19%)
31

Cryoprecipitate
0 (0.00%)
0 (0.00%)
13 (100%)
13

Platelets
1 (6.67%)
0 (0.00%)
14 (93.33%)
15

Number/Total (%)
12/107 (11.21%)
25/107 (23.36%)
70/107 (65.42%)
107/107 (100%)
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Figure 4. Level of Evidence Utilized for All Blood Product Recommendations

Of the 107 recommendations, table 12 and figure 5 demonstrate that 36
(33.64%) recommendations were classified as a “strong” recommendation to perform
the intervention, 46 (42.99%) recommendations were classified as an “intermediate”
recommendation to perform the intervention, and 25 (23.36%) recommendations were
classified as a “weak” recommendation to perform the intervention.

Table 12. Strength of Recommendations for All Blood Products
Strength of
Recommendation

Packed Red
Blood Cells

STRONG

10 (20.83%)

INTERMEDIATE

Fresh
Frozen
Plasma

Cryoprecipitate

Platelets

Number/Total
(%)

9 (29.03%)

7 (53.85%)

10 (66.67%)

36/107 (33.64%)

31 (64.58%)

10 (32.26%)

5 (38.46%)

0 (0.00%)

46/107 (42.99%)

WEAK

7 (14.58%)

12 (38.71%)

1 (7.69%)

5 (33.33%)

25/107 (23.36%)

Total

48

31

13

15

107/107 (100%)
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Figure 5. Strength of Recommendations for All Blood Products

Recommendations Regarding Clinical Use of Red Blood Cells
Table 10 demonstrates that a total of 48 of the 107 recommendations were
relevant to packed red blood cell use. Of the 48 recommendations, table 11 and figure
6 demonstrate that 4 (8.33%) recommendations were generated from “strong” level of
evidence, 24 (50.00%) recommendations were generated by “intermediate” level
evidence, and 20 (41.67%) recommendations were generated by “low” level evidence.
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Figure 6. Level of Evidence Utilized for Packed Red Blood Cell Recommendations

Of the 48 recommendations, table 12 and figure 7 demonstrate that 10 (20.83%)
recommendations were classified as a “strong” recommendation to perform the
intervention, 31 (64.58%) recommendations were classified as an “intermediate”
recommendation to perform the intervention, and 7 (14.58%) recommendations were
classified as a “weak” recommendation to perform the intervention. Of the 10 “strong”
recommendations, 1 (10.00%) recommendation was based on “strong” level of
evidence, 3 (30.00%) recommendations based on “intermediate” level of evidence, and
6 (60.00%) recommendations based on “low” level of evidence (Figure 8).
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Figure 7. Strength of Recommendations for Packed Red Blood Cells

Figure 8. Level of Evidence for “Strong” Recommendations regarding use of RBC

Appendix table 1 summarizes the eleven international guideline
recommendations for the clinical use of packed red blood cells. Of the guidelines
reviewed, 7 of 10 international guidelines have commented on the indications and
utilization of packed red blood cells. A target Hb level of 7-9g/dL is recommended
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(Dellinger, Level 1B; Spahn, Grace 1C) 51,56, but other target ranges such as Hb 6-10g/dL
(ASA, strongly) or 7-10g/dL (Australia, Level IV) has also been recommended as well.
51,54-56

Five guidelines stated RBC should be administered when the hemoglobin level is
<7g/dL (Table 13). Napolitano et al recommended consideration of transfusion with a
Hb <7g/dL in critically ill patients with acute hemorrhage, with hemodynamic instability,
with inadequate oxygen delivery (Level 1), requiring mechanical ventilation or
resuscitated critically ill trauma and stable cardiac patients without acute myocardial
ischemia (Level 2), and Ferraris et al stated it was reasonable for transfusion with a Hb
<7g/dL in most post-operative patients (Class 2A, C), and not unreasonable for patients
on cardiopulmonary bypass with risk for critical end-organ ischemia/injury (Class 2B, C).
52,53

Dellinger et al strongly recommended the threshold for giving RBC be Hb<7g/dL

with a target hemoglobin of 7-9g/dL in adults. They also suggested that a higher
hemoglobin level may be required in the setting of myocardial ischemia, severe
hypoxemia, acute hemorrhage, cyanotic heart disease, or lactic acidosis in patients
(Level 1B, Strong). 56
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Table 13. Guidelines recommending transfusion threshold of Hb <7 g/dL
Organization
Napolitano (USPTF)

Recommendation
Level 1 (convincingly justifiable
based on scientific evidence)
Level 2 (reasonable scientific
evidence and strong expert opinion)

Dellinger (GRADE)

Strong / Grade 1 (Recommend;
benefits do or do not outweigh
harm and burden)

Ferraris (ACC/AHA)

Class 2B (Usefulness/efficacy is less
well established by
evidence/opinion)
-

New Zealand (NHMRC)

Evidence
Class 1, Class 2 (Prospective
RCT, strong prospective and
retrospective analysis)
Class 2, Class 3 (Strong
prospective and retrospective
analysis, retrospective data
collection)
Class B (Moderate; RCT with
important limitations or very
strong evidence from
observational studies or case
series)
Level C (Consensus opinions of
experts)
Level IV (Evidence obtained
from case series, either posttest or pretest and post-test)

In Table 14 Napolitano et al suggested that a transfusion threshold of Hb </=
8g/dL may be beneficial in patients with acute coronary syndromes who are anemic on
hospital admissions (Level 3).52 More “restrictive” hemoglobin transfusion triggers were
recommended by several guidelines.
Table 14. Guidelines recommending transfusion threshold of Hb </= 8g/dL
Organization
Napolitano (USPTF)
British Columbia (AHCPR)

Recommendation
Level 3 (Supported by data but lacking
adequate scientific evidence)
Grade C (Absence of directly
applicable clinical studies of good
quality)

Evidence
Class 3 (retrospective data
collection)
Level IV (Evidence from expert
committee reports or opinions
and/or clinical experiences of
respected authorities)

In Table 15 Ferraris et al stated that for hemoglobin levels <6g/dL, transfusion
with RBC is reasonable and can be life-saving (Class 2A, C), reasonable and life-saving
for cardiac operations (Class 2A, C), reasonable during cardiopulmonary bypass with
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moderate hypothermia except in patients at risk for decreased cerebral oxygen delivery,
such as those with histories of cardiovascular disease, diabetes mellitus, cerebrovascular
disease, and carotid stenosis (Class 2A, C), and additionally the ASA Task Force strongly
agreed upon in the setting of a young, healthy patient especially when the anemia is
acute and without low cardiopulmonary reserve and high oxygen consumption
(strongly). 53,54
Table 15. Guidelines recommending transfusion threshold of Hb <6 g/dL
Organization
Ferraris (ACC/AHA)
British Columbia (AHCPR)

ASA

Recommendation
Class 2A (weight of evidence/opinion is
in favor of usefulness/efficacy)
Grade C (absence of directly applicable
clinical studies of good quality)

Strongly agree

Evidence
C (consensus opinions of experts)
Level IV (evidence from expert
committee reports or opinions
and/or clinical experiences of
respected authorities)
Insufficient

In Table 16 four guidelines did not support the use of 10g/dL as a hemoglobin
transfusion trigger for RBC. Napolitano et al stated there is no benefit of a “liberal”
transfusion when Hb >10g/dL in critically ill patients on mechanical ventilation,
resuscitated critically ill trauma patients, critically ill patients with stable cardiac disease,
or in patients with moderate to severe traumatic brain injury (Level 2). 52 The ASA Task
Force strongly agreed that RBC are usually unnecessary when the hemoglobin level is
more than 10g/dL (strongly), Stainsby et al stated it was rarely indicated when Hb
>10g/dL (Level 1), and the Australian guideline stated that it is likely inappropriate to
transfuse at that hemoglobin level unless there are specific indications (Level I). 47,54,55
However, Ferraris et al stated that it is not unreasonable to transfuse red cells in certain
patients with clinical non-cardiac end-organ ischemia, such as the central nervous and
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gastrointestinal system, whose hemoglobin level is as high as 10g/dL (Class 2B, C). 53
However this statement was modified with the disclaimer that such a “liberal
transfusion” it is unlikely to improve oxygen transport and is not recommended for
those purposes (Class 2B, C). 53
Table 16. Guidelines recommending transfusion threshold of Hb ≠ 10 g/dL
Organization
Napolitano (USPTF)

Recommendation
Level 2 (reasonable scientific evidence
and strong expert opinion)

Ferraris (ACC/AHA)

Class 3 (Conditions for which there is
evidence and/or general agreement
that the procedure/treatment is not
useful/effective, and in some cases
harmful)
Grade C (Body of evidence provides
some support for recommendation but
care should be take in its application)

British Columbia (AHCPR)

New Zealand (NHMRC)

ASA

Strongly agree

Evidence
Class 2, Class 3 (Strong prospective
and retrospective analysis,
retrospective data collection)
C (Consensus opinion of experts)

Level IV (Evidence obtained from
case series, either post-test or
pretest and post-test)
Level I (Evidence obtained from a
systematic review of all relevant
RCT)
Insufficient

Recommendations Regarding Clinical Use Fresh Frozen Plasma
Table 10 demonstrates that a total of 31 of the 107 recommendations were
relevant to fresh frozen plasma use. Of the 31 recommendations, table 11 and figure 9
demonstrate that 7 (22.58%) recommendations were generated from “strong” level of
evidence, 1 (3.23%) recommendation was generated by “intermediate” level evidence,
and 23 (74.19%) recommendations generated by “low” level evidence.
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Figure 9. Level of Evidence Utilized for Fresh Frozen Plasma Recommendations

Of the 31 recommendations, table 12 and figure 10 demonstrate that 9 (29.03%)
of the recommendations were classified as a “strong,” 10 (32.26%) recommendations
were classified as an “intermediate,” and 12 (38.71%) recommendations were classified
as a “weak.” Of the 9 “strong” recommendations, none of recommendations was based
on “strong” level of evidence, 3 (33.33%) recommendations based on “intermediate”
level of evidence, and 6 (66.67%) recommendations based on “low” level of evidence
(Figure 11).
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Figure 10. Strength of Recommendations for Fresh Frozen Plasma

Figure 11. Level of Evidence for “Strong” Recommendations regarding FFP

Appendix table 2 summarizes recommendations for the clinical use of fresh
frozen plasma from the eleven international guidelines. Six of 10 guidelines mention
recommendations on the use of fresh frozen plasma, however only 3 of these six
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guidelines give detailed recommendations on its use. Three guidelines recommend
transfusion and treatment with plasma in trauma patients requiring massive transfusion
(Roback, Moderate) especially to maintain INR and PTT <1.5 (Table 17) or upper limit of
the reference range or increase fibrinogen level to 1g/L (British Columbia, Grade B Level
IIB), and to patients with massive bleeding or significant bleeding complicated by
coagulopathy (PT or aPTT >1.5 control) (Table 17) (Spahn, Grace 1C). 48,57,58 However in
other trauma settings, Roback et al cannot recommend for or against transfusion of
plasma at a plasma:RBC ratio of 1:3 or more during massive transfusion (Low) or for the
use of plasma transfusion in surgical/trauma patients in the absence of massive
transfusion (Very low). 50
Table 17. Guidelines recommending transfusion threshold of PT/aPTT >1.5
Organization
Spahn (GRADE)

Recommendation
Strong / Grade 1 (Recommend; benefits do or
do not outweigh harm and burden)

British Columbia
(AHCPR)

Grade C (Body of evidence provides some
support for recommendation but care should
be take in its application)

Evidence
Class C (Low; current evidence from
observational studies, case series or just
opinion)
Level IV (Evidence obtained from case
series, either post-test or pretest and posttest)

Roback et al recommended that plasma be transfused in patients with warfarin
anticoagulation-related intracranial hemorrhage (low), and in the Australian guidelines
it suggested that transfusion also in the presence of potentially life-threatening bleeding
(Level IV), but Roback et al cannot recommend for or against transfusion of plasma to
reverse warfarin anticoagulation in patients without intracranial hemorrhage (very low).
50,55

The British Columbian and Australian guidelines give specific recommendations
regarding congenital and acquired deficiencies. Fresh frozen plasma is indicated for
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single factor congenital deficiencies where a specific or combined factor concentrate is
not available (British Columbia, Grade C Level IV; Australia. Level IV). 48,55 Fresh frozen
plasma is also indicated for multiple factor deficiencies, hypo/dysfibrinogenemias,
and/or disseminated intravascular coagulopathy associated with severe bleeding (British
Columbia, Grade C Level IV; Australia, Level IV). 48,55 Use of fresh frozen plasma for
treatment of thrombotic thrombocytopenia purpura is controversial, but transfusion of
fresh frozen plasma may be initiated for treatment (British Columbia, Grade B Level IB;
Australia Level IV). 48,55 For vitamin K deficiency, fresh frozen plasma should not be used
to correct inadequate vitamin K intake even if clotting factors are prolonged unless
urgent invasive procedures are required or the patient is bleeding (British Columbia,
Grade B Level IIA). 48 With regards to liver disease, especially in the setting of a liver
biopsy with a patient with marked coagulopathy, the prophylactic use of frozen plasma
may be utilized prior to a procedure based on the clinician’s judgment (British
Columbia, Grade B Level IIA; Australia Level IV). 48,55
In the British Columbia guidelines fresh frozen plasma should not be routinely
used in cardiopulmonary bypass surgery (British Columbia, Level IIB). The Australian
guideline recommends the use of frozen plasma only in the presence of bleeding and
abnormal coagulation following cardiac bypass surgery (Australia, Level IV). 48,55 Fresh
frozen plasma is generally not considered appropriate for the treatment of
hypovolemia, plasma exchange procedures or treatment of immunodeficiency states
(Australia, Level IV). 55
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Recommendations Regarding Clinical Use of Platelets
Table 10 demonstrates that a total of 15 of the 107 recommendations were
relevant to platelet use. Of the 15 recommendations, table 11 and figure 12
demonstrate that 1 (9.67%) recommendation was generated from “strong” level of
evidence, no recommendation was generated by “intermediate” level of evidence, and
14 (93.33%) recommendations were generated by “low” level of evidence.
Figure 12. Level of Evidence Utilized for Platelet Recommendations

Table 12 and figure 13 demonstrate that 10 (66.67%) recommendations were
classified as “strong” recommendations, no recommendations were classified as an
“intermediate”, and 5 (33.33%) recommendations were classified as “weak”
recommendations. Of the 10 “strong” recommendations, 1 (10.00%) recommendation
was based on “strong” level of evidence, and 9 (90.00%) recommendations based on
“low” level of evidence (Figure 14).
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Figure 13. Strength of Recommendations for Platelets

Figure 14. Level of Evidence for “Strong” Recommendations regarding use of Platelets

Appendix table 3 summarizes the eleven international guideline
recommendations for the clinical use of platelets. Four of the 10 guidelines reviewed
commented in the use of platelets with varying triggers for transfusion. Dellinger et al
weakly recommended administering platelets when counts <5,000/mm3 regardless of
bleeding, counts 5,000-30,000/mm3 if there is a significant bleeding risk, and
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</=50,000/mm3 if prior to surgery or invasive procedures (Level 2D Weak). 56 The
Australian guideline also recommends maintaining counts >50,000/mm3 for patients
undergoing surgery or invasive procedures (Australia, Level IV), counts >50,000/mm 3 in
the setting of massive hemorrhage (Australia, Level IV), and counts >100,000/mm 3 in
presence of diffuse microvascular bleeding (Australia, Level IV). 55
There are similar platelet transfusion thresholds recommendations for patients
with trauma or brain injury. The British Committee recommends maintaining a count
>75,000/mm3 in for a majority of patients, with a higher target count of 100,000/mm 3
for patients with multiple high-velocity trauma or central nervous system injury (British,
Level IV Grade C).59 Moreover, Spahn et al recommends administering platelets for a
count >50,000/mm3 for a majority of patients (Grade 1C), and counts >100,000/mm3 for
patients with multiple trauma who are severely bleeding or have traumatic brain injury
(Grade 2C). 51
As prophylaxis, the Australian guideline recommends transfusion if counts
<10,000/mm3 in bone marrow failure without risk factors, or counts <20,000/mm 3 in the
presence of bone marrow failure with risk factors (e.g., fever, antibiotics, systemic
hemostatic failure) (Level II). 55 They also state that platelets are not generally
considered appropriate to treat immune-mediated platelet destruction, thrombotic
thrombocytopenia purpura, hemolytic uremic syndrome, or drug-induced or cardiacbypass-induced thrombocytopenia without hemorrhage (Level IV). 55
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Recommendations Regarding Clinical Use of Cryoprecipitate
Table 10 demonstrates that a total of 13 of the 107 recommendations were
relevant to packed red blood cell use. Of the 13 recommendations, table 11 and figure
15 demonstrate that no recommendations was generated from “strong” level of
evidence or “intermediate” level evidence, and all 13 (100.00%) recommendations were
generated by “low” level of evidence.
Figure 15. Level of Evidence Utilized for Cryoprecipitate Recommendations

Table 12 and figure 16 demonstrate that 7 (53.85%) recommendations were
classified as “strong” recommendations, 5 (38.46%) recommendations were classified as
“intermediate,” and 1 (7.69%) recommendation was classified as a “weak”
recommendation. All 7 “strong” recommendations regarding use of cryoprecipitate
were based on “low” level of evidence.
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Figure 16. Strength of Recommendations for Cryoprecipitate

Appendix table 4 summarizes recommendations for the clinical use of
cryoprecipitate from the eleven international guidelines. Four of 10 guidelines mention
indications and recommendations for the use of cryoprecipitate. Three of the guidelines
specify that the transfusion threshold for cryoprecipitate should be used to maintain
fibrinogen >1g/L (British, Grade C Level IV; British Columbia, Grade C Level I; Spahn,
Grade 1C).51,60 The use of transfusion is considered appropriate in patients with
fibrinogen deficiency, inherited or acquired hypofibrinogenemia, dysfibrinogenemia or
disseminated intravascular coagulation where there is clinical bleeding, during an
invasive procedure, or trauma (British Columbia, Grade C Level IV; Australia, Level IV;
Spahn, Grade 1C). 51,55,60
All guidelines advocate the use of cryoprecipitate in the setting of hemophilia,
von Willebrand’s disease, or deficiencies or factor XIII or fibronectin. The advisory group
of British Columbia recommends that cryoprecipitate can be used in patients with von
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Willebrand’s disease if they are unresponsive to desmopressin (British Columbia, Grade
C, Level IV), used in hemophilia A patients in areas where Factor VIII:C concentrates are
not available (British Columbia, Level IV), and use in patients with FXIII deficiency where
specific factor concentrate is usually not readily available in emergent situations (British
Columbia, Grade C, Level IV). 60 The Australian guideline also does not generally
consider it appropriate to use cryoprecipitate in the treatment of hemophilia, von
Willebrand’s disease, or deficiencies of factor XIII or fibronectin unless alternative
therapies are unavailable (Level IV). 55
In addition, clinical algorithms incorporate the use of cryoprecipitate to manage
signs or symptoms of intracranial bleeding in patients during or after administration of
tPA (British Columbia, Grade C Level IV). 60 Cyroprecipitate is not recommended in
sepsis, as recent controlled trials failed to improve renal and pulmonary function and
peripheral hemodynamics in critically ill septic patients (British Columbia, Grade A Level
IV), and is not recommended in the use of preparation for fibrin glue (British Columbia,
Grade B and C Level III and IV). 60

Discussion
Guidelines Working Group Panel
Analysis of the guidelines demonstrates that a significant proportion of the
guidelines do not mention the total number of members involved, members
representing different medical and surgical specialties or societies, and consulting
methodologists comprising the guideline working group (Table 5, Table 6, Figure 1, and
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Figure 2). The majority of the guidelines reviewed list the medical and surgical
specialties represented in their working group (Table 5 and 6). Only half of the
guidelines specified medical specialties such as hematology and internal
medicine/critical care medicine in their methods (Table 6 and figure 2). However, only a
minority of the guidelines’ working group panels included members trained in
anesthesiology, emergency medicine, surgery (thoracic/trauma) or obstetrics. The
inclusion of such specialties is important as physicians in those fields frequently deal
with patients who can present or develop significant bleeding and require massive
transfusion. It is important to note that there was no mention of members in the
working panel representing orthopedic surgery, vascular surgery, oncologic surgery,
solid organ transplant surgery and neurosurgery. The exclusion of these surgical
subspecialties is significant, as members of these specialties regularly use transfusion of
blood components. It is important to include them, to get their perspective, give
credibility to the guidelines and for the uniformity in clinical care.
More surprisingly, there is even less inclusion of methodologists in the process of
guideline development. Only two of eleven guidelines specifically mention that they
consulted methodologists and included them in their working group (Table 5). It is vital
to know if methodologists are involved in the process of guideline development, as they
are trained in critically appraising evidence, such as assessing the significance of
outcomes and factors affecting quality of evidence. In addition, methodologists are also
trained in determining the applicable translation of the evidence in to clinical practice
and grading strength of recommendations, such as assessing risks versus benefits.
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Evidence and Systematic Reviews Utilized to Generate Guidelines
There is a lack of clarity in the methods section about the nature of literature
review employed by the eleven guidelines (Table 7 and 8). A majority of guidelines did
not reveal the databases utilized for their literature search or mention the study designs
of the evidence they utilized to base their recommendations.

Methodology Utilized to Grade Evidence
The six methodologies employed by the eleven international guidelines reviewed
have both their merits and their limitations. The details of the inclusion criteria and
definitions for classification of grading quality of evidence and strength of
recommendations for each methodology as listed below (Tables 18-32).
Table 18. AHRQ Grading of Quality of Evidence
Grade
1a
1B
2A
2B
3
4

Definition
Evidence obtained from meta-analysis of RCT
Evidence obtained from at least one RCT
Evidence obtained from at least one well-designed controlled study without randomization
Evidence obtained from at least one other type of well-designed quasi-experimental study
Evidence obtained from well-designed non-experimental descriptive studies, such as
comparative studies, correlation studies and case studies
Evidence obtained from expert committee reports or opinions and/or clinical experiences of
respected authorities

Table 19. AHRQ Strength of Recommendations
Strength
A

B

C

Definition
Requires at least one RCT as a part of a body of literature of overall good quality
and consistency addressing specific recommendation.
(Evidence levels 1A, 1B)
Requires the availability of well conducted clinical studies but no RCT on the
topic of recommendation
(Evidence levels 2A, 2B, 3)
Requires evidence obtained from expert committee reports or opinions and/or
clinical experiences of respected authorities. Indicates an absence of directly
applicable clinical studies of good quality.
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The USPSTF methodology involves reviewing evidence, estimating the
magnitude of benefits and harms for each preventive service, reaching a conclusion
about the net benefit for each preventive service, and issuing a recommendation about
the service(Tables 20-23). This methodology does not include the type of study design
as a factor influencing grading of evidence or provide recommendations when there is
little or low evidence available.
Table 20. USPSTF Grading Definition After May 2007
Grade
A

B

C

D

I

Definition
Recommends the service. There is high
certainty that the net benefit is
substantial.
Recommends the service. There is high
certainty that the net benefit is
moderate or there is moderate certainty
that the net benefit is moderate to
substantial.
Recommends against routinely
providing the service. There may be
considerations that support providing
the service in an individual patient.
There is at least moderate certainty that
the net benefit is small.
Recommends against the service. There
is moderate or high certainty that the
service has no net benefit or that the
harms outweigh the benefits.
Concludes that the current evidence is
insufficient to assess the balance of
benefits and harms of the service.
Evidence is lacking, of poor quality, or
conflicting, and the balance of benefits
and harms cannot be determined.

Recommendation
Offer or provide this service.

Offer or provide this service.

Offer or provide this service only if other
considerations support the offering or
providing the service in an individual
patient.

Discourage the use of this service.

If the service is offered, patients should
understand the uncertainty about the
balance of benefits and harms.
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Table 21. USPSTF Level of Certainty After May 2007
Level of Certainty
High

Moderate

Low

Definition
The available evidence usually includes consistent results from well-designed, well-conducted
studies in representative primary care populations. These studies assess the effects of the
preventive service on health outcomes. This conclusion is therefore unlikely to be strongly
affected by the results of future studies.
The available evidence is sufficient to determine the effects of the preventive service on
health outcomes, but confidence in the estimate is constrained by such factors as:
 The number, size, or quality of individual studies.
 Inconsistency of findings across individual studies.
 Limited generalizability of findings to routine primary care practice.
 Lack of coherence in the chain of evidence.
As more information becomes available, the magnitude or direction of the observed effect
could change, and this change may be large enough to alter the conclusion.
The available evidence is insufficient to assess effects on health outcomes. Evidence is
insufficient because of:
 The limited number or size of studies.
 Important flaws in study design or methods.
 Inconsistency of findings across individual studies.
 Gaps in the chain of evidence.
 Findings not generalizable to routine primary care practice.
 Lack of information on important health outcomes.
More information may allow estimation of effects on health outcomes.

Table 22. USPSTF Grading Definition Prior to May 2007
Grade
A

B

C

D

I

Definition
Strongly recommends that clinicians provide [the
service] to eligible patients. The USPSTF found
good evidence that [the service] improves
important health outcomes and concludes that
benefits substantially outweigh harms.
Recommends that clinicians provide [the service]
to eligible patients. The USPSTF found at least
fair evidence that [the service] improves
important health outcomes and concludes that
benefits outweigh harms.
Makes no recommendation for or against routine
provision of [the service]. The USPSTF found at
least fair evidence that [the service] can improve
health outcomes but concludes that the balance
of benefits and harms is too close to justify a
general recommendation.
Recommends against routinely providing [the
service] to asymptomatic patients. The USPSTF
found at least fair evidence that [the service] is
ineffective or that harms outweigh benefits.
Concludes that the evidence is insufficient to
recommend for or against routinely providing
[the service].Evidence that the [service] is
effective is lacking, of poor quality, or conflicting
and the balance of benefits and harms cannot be
determined.

Recommendation
Strongly recommended.

Recommended.

No recommendation.

Not recommended.

Insufficient evidence to make
recommendation.

P a g e | 45

Table 23. USPSTF Quality of Evidence Prior to May 2007
Quality of Evidence
Good
Fair

Poor

Definition
Evidence includes consistent results from well-designed, well-conducted studies in
representative populations that directly assess effects on health outcomes.
Evidence is sufficient to determine effects on health outcomes, but the strength of
the evidence is limited by the number, quality, or consistency of the individual
studies, generalizability to routine practice, or indirect nature of the evidence on
health outcomes.
Evidence is insufficient to assess the effects on health outcomes because of
limited number or power of studies, important flaws in their design or conduct,
gaps in the chain of evidence, or lack of information on important health
outcomes.

The ACC/AHA methodology in Table24 involves collection and grading of
evidence for guideline development, which allows one to draw conclusions (i.e.,
guideline recommendations) that are supported by data (i.e., level of evidence). The
ACC/AHA Task Force recommends either assigning the Classification of
Recommendation and Level of Evidence when writing the recommendations, or rather
to state the recommendation and assign the classification afterwards after re-examining
data. Assigning a Classification of Recommendation and Level of Evidence, aids to
provide a more descriptive and quantitative criteria for evidence ratings. In addition,
with the ACC/AHA methodology involving Classification of Recommendations and Levels
of Evidence, any combination of the two rating systems is possible.
Designation of Level of Evidence B or C should not be construed as implying that
the recommendation is weak. It merely implies that certain clinical questions addressed
in the guidelines do not lend themselves to experimentation or have not yet been
addressed by high quality investigations. The clinical questions may be relevant or
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important enough that it is addressed in the guidelines, even though randomized
controlled studies may not be available to answer and support the query.
Table 24. AHA/ACC Grading of Evidence and Strength of Recommendation
Classification
Size of Treatment Effect
Estimate of
Certainty
(Precision)
of
Treatment
Effect

Class I

Class IIA

Class IIB

Class III

Benefit >>>Risk

Benefit>>>Risk

Benefit ≥ Risk

Risk ≥ Benefit

Procedure/Treatment
SHOULD be
performed/administered

Additional studies with
focused objectives
needed

Additional studies with
broad objectives needed;
additional registry data
would be helpful

Procedure/Treatment
should NOT be
performed/administered
since IT IS NOT HELPFUL
and MAY BE HARMFUL

IT IS REASONABLE to
perform
procedure/administer
treatment
Level A
Multiple (3-5) population
risk strata evaluated
General consistency of
direction and magnitude
of effect
Level B
Limited (2-3) population
risk strata evaluated

Recommendation that
procedure or treatment is
useful/effective
Sufficient evidence from
multiple randomized trials
or meta-analyses

Recommendation that
procedure or treatment is
useful/effective
Limited evidence from
single randomized trial or
non-randomized studies

Level C
Very limited (1-2)
population risk strata
evaluated

Recommendation that
procedure or treatment is
useful/effective
Only expert opinion, case
studies, or standard-ofcare

Recommendation in
favor of treatment or
procedure being
useful/effective
Some conflicting
evidence from multiple
randomized trials or
meta-analyses
Recommendation in
favor of treatment or
procedure being
useful/effective
Some conflicting
evidence from single
randomized trial or nonrandomized studies
Recommendation in
favor of treatment or
procedure being
useful/effective
Only diverging expert
opinion, case studies, or
standard –of-care

IT IS NOT UNREASONABLE
to perform
procedure/administer
treatment
Recommendation’s
usefulness/efficacy less
well established
Greater conflicting
evidence from multiple
randomized trials or metaanalyses
Recommendation’s
usefulness/efficacy less
well established
Greater conflicting
evidence from single
randomized trial or nonrandomized studies
Recommendation’s
usefulness/efficacy less
well established
Only diverging expert
opinion, case studies, or
standard-of-care

Recommendation that
procedure or treatment
not useful/effective and
may be harmful
Sufficient evidence from
multiple randomized
trials or meta-analyses
Recommendation that
procedure or treatment
not useful/effective and
may be harmful
Limited evidence from
single randomized trial
or non-randomized
studies
Recommendation that
procedure or treatment
not useful/effective and
may be harmful
Only expert opinion,
case studies, or
standard-of-care

The NHMRC utilizes a system that allows also for Levels of Evidence and Grades
of Recommendation (Tables 25 and 26). The classification system for evidence assigns
levels of evidence according to the type of research question, recognizing the
importance of appropriate research design to that specific clinical question in guideline
development. Grading of recommendations is ascribed not only by the level of
evidence, but takes into consideration the quality of the study and the likelihood that
the results have been affected by bias during its conduct, the consistency of its findings
to those from other studies, the clinical impact of its results, and generalizability of the
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results to the population for whom the guideline is intended, and the applicability of the
results to the Australian or local healthcare system. Thus the grade of the
recommendation is based on an overall assessment of all these components of the body
of evidence being assessed.
Table 25. NHMRC Evidence Hierarchy
LEVEL

Intervention

Diagnostic Accuracy

Prognosis

Etiology

I

A systematic review
of level II studies
A randomized
controlled trial

A systematic review
of level II studies
A study of test
accuracy with: an
independent,
blinded comparison
with a valid
reference standard,
among consecutive
persons with a
defined clinical
presentation
A study of test
accuracy with: an
independent,
blinded comparison
with a valid
reference standard,
among nonconsecutive persons
with a defined
clinical presentation
A comparison with
reference standard
that does not meet
the criteria required
for Level II and III1
evidence

A systematic review
of level II studies
A prospective cohort
study

A systematic review
of level II studies
A prospective cohort
study

All or none

All or none

A pseudorandomized
controlled trial (ie,
alternate allocation
or some other
method)

Analysis of
prognostic factors
amongst persons in a
single arm of
randomized
controlled trial

A retrospective
cohort study

A comparative study
with concurrent
controls:
Non-randomized
experimental trial,
Cohort study, Casecontrol study

Diagnostic casecontrol study

A retrospective
cohort study

A case-control study

A comparative study
without concurrent
controls:
Historical control
study,
Two or more single
arm study

Study of diagnostic
yield (no reference
standard)

Case series, or cohort
study of persons at
different stages of
disease

A cross-sectional
study or case series

Case series

II

III1

A pseudorandomized
controlled trial (ie,
alternate allocation
or some other
method

III2

A comparative
study with
concurrent controls:
Non-randomized
experimental trial,
Cohort study,
Case-control study,
Interrupted time
series with a control
group
A comparative
study without
concurrent controls:
Historical control
study,
Two or more single
arm study,
Interrupted time
series without a
parallel control
group
Case series with
either post-test or
pre-test/post-test
outcomes

III3

IV

Screening
Intervention
A systematic review
of level II studies
A randomized
controlled trial
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Table 26. NHMRC Body of Evidence Matrix and Grades of Recommendation
Component

Evidence Base

Consistency

Grade A

Grade B

Grade C

Grade D

Excellent

Good

Satisfactory

Poor

Body of
evidence can be
trusted to guide
practice

Body of evidence
can be trusted to
guide practice in
most situations

Body of evidence is
weak and
recommendation
must be applied with
caution

One or more
level I studies
with a low risk
or bias or
several level II
studies with a
low risk bias
All studies
consistent

One or two level II
studies with a low
risk of bias or a
systematic
review/several
level III studies
with low risk bias
Most studies
consistent and
inconsistency may
be explained
Substantial
Population/s
studied in the
body of evidence
are similar to the
target population
for the guideline

Body of evidence
provides some
support for
recommendations
but care should be
taken in its
application
One or two level III
studies with a low
risk of bias, or level I
or II studies with a
moderate risk of bias

Some inconsistency
reflecting genuine
uncertainty around
clinical questions
Moderate
Population/s studied
in body of evidence
differ to target
population for
guideline but it is
clinically sensible to
apply this evidence
to target population
Probably applicable
to Australian
healthcare context
with some caveats

Evidence is
inconsistent

Clinical Impact
Generalizability

Very large
Population/s
studied in body
of evidence are
the same as the
target
population for
the guideline

Applicability

Directly
applicable to
Australian
healthcare
context

Applicable to
Australian
healthcare context
with few caveats

Level IV studies, or
level I to III
studies/systematic
reviews with a high
risk of bias

Slight or restricted
Population/s studied
in body of evidence
differ to target
population and hard
to judge whether it is
sensible to generalize
to target population
Not applicable to
Australian healthcare
context

The ASA uses specific terms to specify the grading of evidence in their
formulation of recommendations. When sufficient numbers of studies are available for
evaluation, the terms in table 27 are used to describe the strength of the findings.
When the ASA describes the lack of scientific evidence in the literature, it uses the terms
listed in table 28. When information is collected from consultants and members of the
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ASA, the terms used to describe survey responses for any issue are represented in Table
29. The survey responses are solicited on a five-point scale, ranging from 1 (strongly
disagree) to 5 (strongly agree), with the score of 3 being equivocal.
Table 27. ASA Grading of Evidence
Support

Suggest

Equivocal

Meta-analysis of a sufficient number of randomized controlled trials indicates a
statistically significant relationship (P<0.01) between a clinical intervention and a
clinical outcome.
Information from case reports and descriptive studies permits inference of a
relationship between an intervention and an outcome. This type of qualitative
information does not permit a statistical assessment of significance.
Qualitative data are not adequate to permit inference of a relationship between an
intervention and an outcome and (1) there is insufficient quantitative information
or (2) aggregated comparative studies have found no significant differences among
groups or conditions.

Table 28. ASA Strength of Recommendations
Silent
Insufficient
Inadequate

No identified studies address the relationship of interest.
There are too few published to investigate a relationship between an intervention
and outcome.
The available studies cannot be used to assess the relationship between an
intervention and an outcome. There studies either do not meet the criteria for
content as defined in the Focus of these Guidelines or do not permit a clear casual
interpretation of findings due to methodologic concerns.

Table 29. ASA Survey Responses
Strongly Agree
Agree
Equivocal

Disagree
Strongly Disagree

Median score of 5 (at least 50% of the responses are 5).
Median score of 4 (at least 50% of the responses are 4 or 4 and 5).
Median score of 3 (at least 50% of the responses are 3, or no other response
category or combination of similar categories contain at least 50% of the
responses).
Median score of 2 (at least 50% of responses are 2 or 1 and 2).
Median score of 1 (at least 50% of responses are 1).

The GRADE methodology, however, has become the methodology that is
currently being accepted by an increasing number of organizations. The GRADE working
group represents an international collaboration of guideline developers, clinicians,
health service researchers, and methodologists. The GRADE system for grading the
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quality of evidence comprises four steps: identifying important and critical outcomes;
preliminary grading of evidence in terms of study design, quality, consistency and
directness; taking in to account other factors that can increase or decrease evidence;
and the overall quality of the evidence. The definition for quality of evidence is listed in
Table 30. The strength of recommendation, categorized as strong, weak or conditional
recommendations for or against an intervention or treatment, is defined as the extent
to which one can be confident that the desirable effects of an intervention outweigh the
undesirable effects. It requires the consideration of the benefits and risks of an
intervention for all patient-important endpoints, the associated values and preferences
and resource use.
Other previous systems of grading rely almost exclusively on overall study design
to determine quality of evidence, however in the GRADE system study design remains
critical but not a sole factor in judging the quality of evidence. In the GRADE system,
expert opinion is not a category of quality of evidence but rather an interpretation of
existing evidence. In addition there are factors that can reduce or increase quality of
evidence for each study design, that overcome the limitations of grading quality of
evidence with just study design (Tables 31 and 32). This is important, as a well-designed
and executed non-randomized trial or observational study, may provide better quality
evidence than a poorly executed randomized-controlled trial.
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Table 30. GRADE Quality of Evidence
Grade
High
⊕⊕⊕⊕
Moderate
⊕⊕⊕
Low
⊕⊕
Very Low
⊕

Definition
Further research is unlikely to change our confidence in the estimate of effect.
Further research is likely to have an important impact on our confidence in the
estimate of effect and may change the estimate.
Further research is very likely to have an important impact on our confidence in
the estimate of effect and is likely to change the estimate.
Any estimate of effect is very uncertain.

Table 31. Factors that can reduce the Quality of the Evidence
Factor
Limitations in study design or execution (risk of bias)
Inconsistency of results
Indirectness of evidence
Imprecision
Publication bias

Consequence
↓ 1 or 2 levels
↓ 1 or 2 levels
↓ 1 or 2 levels
↓ 1 or 2 levels
↓ 1 or 2 levels

Table 32. Factors that can increase the Quality of the Evidence
Factor
Large magnitude of effect
All plausible confounding would reduce the demonstrated effect or
increase if no effect was observed
Dose-response gradient

Consequence
↑ 1 or 2 levels
↑ 1 level
↑ 1 level

The advantage of the GRADE system versus other methodologies is its
transparency. It considers many other factors other than study design of literature in
determining the strength and quality as evidence. In addition, it generates appropriate
recommendations for course of action in the setting of very little evidence available.
Some of the medical professional associations that have shifted to using the GRADE
system include the following international organizations listed in Appendix table 5.
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Practice Guideline Recommendations
Almost half (48.86%) of the total recommendations reviewed pertain only to the
transfusion of packed red blood cells (Table 10 and figure 3). The rest of the
recommendations reviewed pertain to coagulation blood components such as fresh
frozen plasma (28.97%), platelets (12.02%), and cryoprecipitate (12.15%). This suggests
that there is mounting literature regarding the transfusion of packed red blood cells, but
substantial evidence is still lacking regarding the appropriate use and safety of fresh
frozen plasma, platelets, and cryoprecipitate.
Of the 107 recommendations reviewed, a majority (65.42%) of the
recommendations were based from “low” level of evidence. This “low” level of
evidence may include case series or reports, expert reports or opinions, and evidence
that is limited in power or demonstrates flaws in the study design. Only 12 (11.21%)
recommendations are based on “strong” level of evidence, such as meta-analyses and
randomized controlled trials. Our analysis suggests the lack of relationship/association
between the quality of evidence reviewed and the strength of recommendations
generated by the guideline working panels (Table 11, Table 12, Figure 4, Figure 5).
Though 82 (76.63%) recommendations are classified as “strong” or “intermediate”
recommendations, they are based solely on “low” level of evidence (Table 12, Figure 5).

Recommendations Regarding Clinical Use of Blood Products
A majority (85.41%) of recommendations for packed red blood cells deemed as
“strong” and “intermediate” are based almost entirely (91.67%) on “intermediate” and
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“low” level of evidence. Of the “strong” recommendations regarding the use of packed
red blood cells, majority were based on a “low” level of evidence. More than half
(61.29%) of recommendations for fresh frozen plasma deemed “strong” and
“intermediate” are based exclusively (74.19%) on “low” level of evidence. All
recommendations pertaining to cryoprecipitate transfusion are based solely on “low”
level of evidence. A majority of “strong” recommendations for platelet transfusion are
based almost entirely (93.33%) on “low” level evidence. With the slight exception of
packed red blood cells, all guidelines undividedly reported “strong” and/or
“intermediate” recommendations to transfuse coagulation products on the basis of
“low” level evidence.
In addition, there was multiple hemoglobin level transfusion triggers are
reported amongst the eleven guidelines, and even within a guideline. There was clearly
a discrepancy between guideline recommendations about transfusing for a particular
hemoglobin level, as well as, a discrepancy between the quality and strength of
evidence to support the recommendation. For example in regard to use of 6g/dL of
hemoglobin as a packed red blood cell transfusion trigger, the two organizations utilized
the same quality of evidence (consensus opinions of experts) yet generated different
recommendations. One organization favored the use and efficacy of the intervention,
while the other organization gave the intervention its lowest level of
recommendation.53,54
In addition, one organization reported two different hemoglobin levels as
transfusion triggers in the context of different clinical settings.53 Both recommendation
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statements were based on “consensus opinions of experts.” The recommendation to
transfuse at hemoglobin < 6g/dL is graded Class 2A supporting the intervention in favor
of its usefulness and efficacy, whereas the recommendation to transfuse at hemoglobin
< 7g/dL is graded Class 2B giving weaker support to the recommendation as the
usefulness and efficacy. It is unclear through analysis of these eleven guidelines what
specific hemoglobin level should be utilized as the threshold hemoglobin level to trigger
transfusion of packed red blood cells. The only consensus is not to transfuse if the Hb is
> 10gm/dl.
The recommendations generated for the use of fresh frozen plasma, platelets,
and cryoprecipitate are based on even weaker level of evidence compared to the
recommendations generated for use of packed red blood cells. The recommendations
for coagulation products are insufficient, both in number of total recommendations and
in strength of recommendations. Two organizations have stated a definite threshold to
transfuse fresh frozen plasma (PT or aPTT is > 1.5 normal). 58,61 However, the data come
from the same quality of evidence (case series, observational studies, and consensus
opinion of experts). In the eleven guidelines we evaluated, there is no consensus
regarding a definite platelet level or a fibrinogen which should trigger transfusion.

Limitations of Study
The following are the limitations of this investigation. Of the guidelines included,
only guidelines published in the English language were reviewed, as well as, only
guidelines published in the last ten years were reviewed. We have only reviewed
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guidelines relevant to adult patients. In addition, only two reviewers screened the initial
literature searches performed on PubMed/Medline, Scopus, Cochrane Central and the
National Guideline Clearinghouse, and determined that the final eleven guidelines to be
selected for inclusion in the study.
In order to compare different guidelines we had to develop a uniform scoring
system. These definitions were created to readily compare the eleven guidelines that
had all used different grading and classification methodology systems. However, this
scoring system has not been externally validated and is kind of unique. However we feel
that the system is valid as it generally encompasses and closely follows the definitions
that were used by the original seven methodologies.

Implications of Study
Analysis of these eleven international guidelines suggests that currently a
large body of recommendations concerning blood component therapy is based solely on
“low” quality evidence. Clearly there is a significant scarcity of strong evidence as well
as clearly explicit recommendations to guide clinician practice of transfusion of blood
products. In addition, many of the guidelines are not clear in reporting their methods of
literature search, working group composition, and evidence review process. There is
also a lack of consistency in current guidelines’ use of evidence grading methodologies.
This adds confusion to the interpretation of the recommendations generated for
clinicians and applications of guidelines.
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The use of different grading methodologies generates discrepancies in
recommendations. The use of multiple and different grading methodologies does not
allow for clinicians to readily compare recommendations generated from guidelines. In
addition, each methodology systems assigns quality of evidence based on a variety of
factors and thus can result in varying strength of recommendations for the same
intervention even though derived from the similar data. These multiple
recommendations with varying strengths from guidelines can translate to
inconsistencies in practices amongst practitioners.
This study demonstrates that there currently is lack of robust and
methodologically clear transfusion guidelines. Quality randomized controlled trials
should be conducted especially with regards to the appropriate use and safety of fresh
frozen plasma, cryoprecipitate and platelets. In addition, the use of multiple evidence
grading methodologies creates discrepancies in recommendations and confusion
amongst clinicians. Under these circumstances, it seems logical that future directions
with guideline development should be aimed at the utilization of a universal
methodology system to grade evidence and classify recommendations. Moreover, there
should be more integration of surgical subspecialty physicians in working group panels
in the development of guideline recommendations. In conclusion, future research
should also be stimulated and directed at providing more abundant and high quality
evidence regarding the use and safety of blood components in the perioperative setting.
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Appendix
Appendix Table 1. Summary of Guideline Recommendations and Indications for
Clinical Use of Packed Red Blood Cells
Napolitano

Dellinger

Ferraris

Spahn

Methodology
Trigger

USPTF
Hb < 7g/dl
Hb </= 8 g/dl

GRADE
Hb < 7g/dl
Target Hb 7-9 g/dl

ACC/AHA
Hb < 6 g/dl
Hb < 7g/dl

GRADE
Target Hb 7-9
g/dl

Hemorrhagic shock

Hb < 7g/dl Acute
hemorrhage,
hemodynamic
instability or
inadequate oxygen
delivery (except in
acute myocardial
ischemia)

Hb < 7g/dl
For acute
hemorrhage,
higher Hg level
may be required

British
Columbia
AHCPR
Hb < 6 g/dl
Maintain at
Hb > 8g/dl
Rarely >10
g/dl

ASA

New Zealand

ASA
Hb <6g/dl

NHMRC
Hb < 7 g/dl
(if asymptomatic
lower trigger
appropriate)
Target Hb 7-10 g/dl

Hb
>10g/dl

Inappropriate when
Hb > 10 g/dl

Level 1: Class 1 RCT,
strong Class 2
Observational, Pro
Cohort, prevalence,
case-control
retrospective
Critically
ill/mechanical
ventilation

Myocardial
ischemia/cardiac
disease

Hb < 7g/dl Patients
with stable cardiac
disease
Avoid Hb as trigger
Level 2: Class 2, Class
3
Acute coronary
disease and anemia
use trigger of Hb </=
8 g/dl

Hb < 7g/dl
Higher Hb level
may required

Level 3
Post-operative

Hb < 6 g/dl
For cardiac
operations
Hb < 7 g/dl
No high-level
evidence
Hb < 6 g/dl
Except in patients
with cardiovascular
disease, diabetes
mellitus,
cerebrovascular
disease, carotid
stenosis

Cardiopulmonary
bypass

Hb target >/= 7 g/dl
For patients at risk
for critical end-organ
ischemia
Lactic acidosis

Not indicated

Hb < 7g/dl
Higher Hb level
may required
Sepsis (no clear
evidence transfusion
increases tissue
oxygenation)
Traumatic brain
injury and
intracranial
hemorrhage (no
clear evidence it
improves outcomes)

Unlikely to improve
tissue pxygenation
with Hb > 10 g/dl
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Appendix Table 2: Summary of Guideline Recommendations and Indications for
Clinical Use of Fresh Frozen Plasma

Methodology
Trigger

Roback

Dellinger

Spahn

GRADE
-

GRADE
-

GRADE
PT/aPTT <
1.5

Massive transfusion

Trauma

For massive
or significant
bleeding
complicated
by
coagulopath
y

British
Columbia
AHCPR
PT/aPTT < 1.5

ASA
Elevate
d aPTT
(agree)

NHMRC
-

Suggests for
massive
transfusion
In emergency

DIC

Only with active
bleeding and
coagulation abnl
As interim
measure, a slow
infusion
Severe bleeding
or hemostasis
for emergency
surgery or
invasive
procedure
Bleeding or
urgent invasive
procedure
Prophylactic
measure is
there is marked
abnl or
coagulopathy
Cardiopulmonar
y bypass
Invasive bedside
procedures with
mild to
moderate abnl

TTP

Suggests
transfusion

Vitamin K deficiency

Liver biopsy

Not indicated

New Zealand

INR/PTT < 1.5
Fibrinogen >/=
1.0 g/L
Replacement of
patient’s whole
blood volume
within 24 hours

Inherited deficiencies

Warfarin
anticoagulation/intracrani
al hemorrhage

ASA

Acute
pancreatitis,
organophosphat
e poisoning,
coagulopathy
associated with
acetaminophen
overdose,
intracranial
hemorrhage
after severe
closed head
injury without
coagulopathy,
nonsurgical non
cardiac patients
in ICU

To correct
lab clotting
abnormalit
y unless
bleeding is
present or
planned
invasive
procedure

Recommended
before high-risk
procedures
Recommended

Recommended

For immediate
reversal in
presence of lifethreatening
bleeding

Hypovolemia,
plasma exchange
procedures,
treatment of
immunodeficienc
y states
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Appendix Table 3: Summary of Guideline Recommendations and Indications for
Clinical Use of Platelets

Methodology
Trigger

No bleeding
Significant
bleeding risk
Pre-operative
Invasive
procedures
DIC
Trauma
Sepsis
Traumatic
brain injury
Bone marrow
failure

Not indicated

Dellinger

Spahn

GRADE
< 5000/mm3
regardless of
bleeding

GRADE
<50000/mm3

5000-30000

<100000/mm3

British
Columbia
AHCPR
< 75000/mm3

ASA

New Zealand

ASA
<50000/mm3

NHMRC

</=
50000/mm3
</=
50000/mm3

<50000/mm3
<50000/mm3

<100000/mm3

<100000/mm3

<100000/mm3

<100000/mm3
<10000/mm3
without risk
factors

>100000/mm3

<20000/mm3 with
risk factors (fever,
antibiotics,
systemic
hemostatis
failure)
Immunemediated platelet
destruction,
thrombotic,
thrombotic
thrombocytopenic
purpura,
hemolytic uremic
syndrome, druginduced or cardiac
bypass
thrombocytopenia
without
hemorrhage
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Appendix Table 4: Summary of Guideline Recommendations and Indications for
Clinical Use of Cryoprecipitate
Methodology
Trigger
Inherited/acquired
deficiency
Dysfibrinogenemia
DIC

British Columbia
AHCPR
Fibrinogen < 1.0 g/L
< 1.0 g/L

ASA
ASA
Fibrinogen <0.8g/L

< 1.0 g/L
< 1.0 g/L

When considered
clinically appropriate

Sepsis
Invasive procedure
Trauma
Intracranial hemorrhage

Hemophilia

Von Willebrand’s disease

Factor XIII or fibronectin
deficiency

Not indicated

Fibrinogen <0.81.0g/L
During or after
administration of tPA
Used if unresponsive
to desmopressin
Used if FVIII:C
concentrates not
available
Used if FVIII:C
concentrates not
available
Fibrin glue. sepsis

New Zealand
NHMRC
-

Fibrinogen >1.5g/L

When considered
clinically appropriate
When considered
clinically appropriate

Hemophilia, von
Willebrand’s disease,
deficiencies of XIII or
fibronectin

Cochrane
SHULZ
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Appendix Table 5. Organizations that have endorsed or that are using GRADE
Organizations
World Health Organization – International
Endocrine Society – USA
American College of Chest Physicians – USA
UpToDate – Putting Clinical Information Into Practice - USA
Agenzia sanitaria regionale, Bologna – Italia
Ministry of Health and Long-term Care, Ontario – Canada
Surviving Sepsis – International
Arztliches Zentrum fur Qualitat in der Medizin – Germany
American Thoracic Society – USA
American College of Physicians – USA
The Cochrane Collaboration – International
Kidney Disease: Improving Global Outcome – International
European Society of Thoracic Surgeons – International
British Medical Journal – UK
Journal of Infection in Developing Countries – International
Agency for Healthcare Research and Quality (AHRQ) – USA
Society of Critical Care Medicine (SCCM) – USA
National Institute for Clinical Excellence (NICE) – UK
Norwegian Knowledge Centre for the Health Services – Norway
The University of Pennsylvania Health System Center for Evidence-based Practice – USA
German Center for Evidence-based Nursing “sapere aude” – Germany
Evidence-based Nursing Sudirol, Alto Adige – Italy
Society for Vascular Surgery – USA
BMJ Clinical Evidence – UK
EBM Guidelines – Finland/International
Polish Institute for EBM – Poland
European Respiratory Society (ERS) – Europe
Japanese Society for Temporomandibular Joint – Japan
National Board of Health and Welfare – Sweden
COMPUS at The Canadian Agency for Drugs and Technologies in Health (CADTH) – Canada
Infectious Diseases Society of America – USA
Spanish Society for Family and Community Medicine – Spain
Emergency Medical Services for Children National Resource Center – USA
SBU – The Swedish Council on Technology Assessment in Health Care – Sweden
The Scottish Intercollegiate Guidelines Network (SIGN) – UK
Evidence-Based Tuberculosis Diagnosis (tbevidence.org) – Canada
National & Gulf Center for Evidence Based Health Practice (NGCEBHP) – Saudi Arabia
American Society for Gastrointestinal Endoscopy – USA
European Association for the Study of the Liver – Europe
CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC) – USA
Finnish Office for Health Technology Assessment – Finland
NHS Quality Improvement Scotland – UK
The American Association for the Study of Liver Diseases – USA
The Canadian Cardiovascular Society – Canada
The World Allergy Organization (WAO) – International
Kaiser Permanente – USA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) – Europe
World Interactive Network Focused on Critical Ultrasound – International
Critical Ultrasound Journal – Italy
American Society for Colposcopy and Cervical Pathology – USA
The Dutch Institute for Healthcare Improvement CBO – The Netherlands
Kleijnen Systematic Reviews Ltd – UK
American Gastroenterological Association – USA
Ludwig Boltzmann Institut – Austria
Canadian Task Force on Preventative Health Care – Canada
Canadian Society of Nephrology – Canada
The National Kidney Foundation / KDOQI – USA
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